# Hisham Elhaddad

> Hisham Elhaddad is a Series B investor at HOF Capital (New York) backing Biotechnology and SaaS. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [HOF Capital](https://shizune.co/investors/profile/hof-capital)
- Location: New York, United States
- Total investments: 8
- Last investment: Apr 2026
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/hishamelhaddad
- X (Twitter): https://twitter.com/helhaddad7
- Website: https://x.com/helhaddad7

Hisham Elhaddad is a Series B investor at HOF Capital in New York focused on Biotechnology and SaaS. Hisham Elhaddad is based out of New York, New York and is the Co-Founder and Managing Partner of HOF Capital. Hisham previously worked at Entrepreneurs Roundtable Accelerator as a Investment Associate. Hisham Elhaddad attended the Boston University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 25% |
| SaaS | 1 | 13% |
| Energy | 1 | 13% |
| Medical | 1 | 13% |
| Nuclear | 1 | 13% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 38% |
| Series A | 2 | 25% |
| Secondary Market | 2 | 25% |
| Series C | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 50% |
| Croatia | 2 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bugatti Rimac | Bugatti Rimac is a Motor Cycle Manufacturing Company. |  | Secondary Market | Apr 24, 2026 |  |
| Rimac Group | Rimac is a technology powerhouse that manufactures electric hypercars and provides full technology solutions to global automotive manufacturers. Founded in 2009 with headquarters in Croatia, Rimac started as a garage project and grew into a globally recognized technology leader, built upon the passion and vision of the company's Founder andCEO Mate Rimac. It has challenged the status-quo with the vision to revolutionize and reinvent the sports car with its unique technology thus successfully tackling the electrification challenge set upon the automotive industry. |  | Secondary Market | Apr 24, 2026 |  |
| Commonwealth Fusion Systems | Commonwealth Fusion Systems develops fusion energy systems using high-temperature superconducting (HTS) magnets to create compact tokamak reactors. It is building SPARC, a demonstration device designed to achieve net energy gain from fusion and laying the groundwork for ARC, a grid-connected fusion power plant targeting early 2030s operation. Thecompany partners with MIT and manufactures its HTS magnets and related components, applying peer-reviewed science in its firewalling of plasma and reactor engineering. It has introduced innovations like the PIT VIPER superconducting cable to support pulsed-power magnet systems and accelerate readiness for commercial fusion. | $863M | Series B | Aug 27, 2025 |  |
| Codesphere | Codesphere is your Zeroconfig Cloud. No config - just code and run web apps from your browser. Team work on distributed full stack Typescript, and benefit from our automatic deployments, scaling, tests, and security / privacy audits. We optimize each and every detail to keep things simple for you. Codesphere is next level programming. | $30.9M | Series A | May 17, 2024 |  |
| BillionToOne | BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $125M | Series C | Mar 30, 2022 |  |
| BillionToOne | BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $55M | Series B | Jun 15, 2021 |  |
| Insitro | Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $143M | Series B | May 26, 2020 |  |
| BillionToOne | BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $15M | Series A | Mar 10, 2020 |  |

8 of 8 investments shown.

## Co-investors
- [468 Capital](https://shizune.co/investors/profile/468-capital) — VC Fund, 3 deals together
- [Fifty Years](https://shizune.co/investors/profile/fifty-years) — VC Fund, 3 deals together
- [Hummingbird Ventures](https://shizune.co/investors/profile/hummingbird-ventures) — VC Fund, 3 deals together
- [Libertus Capital](https://shizune.co/investors/profile/libertus-capital) — VC Fund, 3 deals together
- [Neotribe Ventures](https://shizune.co/investors/profile/neotribe-ventures) — VC Fund, 3 deals together
- [BlueFive Capital](https://shizune.co/investors/profile/bluefive-capital) — VC Fund, 2 deals together

## About HOF Capital

VC Fund · New York, United States

HOF Capital is a global multistage VC firm with $1 billion in AUM that partners with ambitious entrepreneurs from idea to IPO.

5 contacts available at HOF Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Fady Yacoub | Co-Founder and Partner | https://shizune.co/investors/profile/fady-yacoub |
| Hisham Elhaddad | Co-Founder and Managing Partner | https://shizune.co/investors/profile/hisham-el-haddad |
| Onsi Sawiris | Co-Founder and Managing Partner | https://shizune.co/investors/profile/onsi-sawiris |
| Troy Shen | Senior Associate | https://shizune.co/investors/profile/troy-shen-89bb |
| Victor Wang | Partner | https://shizune.co/investors/profile/victor-wang-3 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Hisham Elhaddad invest in?

Hisham Elhaddad invests primarily in Biotechnology, SaaS and Energy startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hisham Elhaddad last invest?

The most recent investment recorded for Hisham Elhaddad closed in Apr 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co